重大事件
即時報告
8-K
2026-06-26
Outlook Therapeutics成功擺脫納斯達克除牌危機 股價連續10日達標
AI 繁中摘要
Outlook Therapeutics（代號：OTLK）於2026年6月26日提交8-K申報，披露已成功擺脫納斯達克除牌危機。🚨
公司早前因普通股連續30個交易日收市買入價低於1美元，違反納斯達克上市規則5550(a)(2)，於2026年2月18日收到除牌通知。然而，最新文件顯示，從2026年6月11日至6月25日期間，其股價已連續10個交易日維持在1美元或以上，符合重新合規條件。納斯達克正式確認該事項已結束，公司可繼續在納斯達克資本市場掛牌。
此消息對投資者屬正面信號 ✅，意味著短期內不會因股價過低而被強制退市，有助穩定市場信心。不過，投資者仍需留意公司基本因素及未來股價表現，因為長期維持合規仍取決於持續的業務進展及資金狀況。
展開英文正文
false 0001649989 0001649989 2026-06-26 2026-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2026 Outlook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37759 38-3982704 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 111 S. Wood Avenue, Unit #100 Iselin, New Jersey 08830 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (609) 619-3990 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock OTLK The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on February 18, 2026, Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq staff had determined to delist the Company’s common stock, par value $0.01 per share (the “Common Stock”) from the Nasdaq Capital Market because it failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in violation of Nasdaq Listing Rule 5550(a)(2). On June 26, 2026, the Company received a letter from the Nasdaq Staff notifying the Company that, because the closing bid price of the Company’s common stock had been at $1.00 per share or greater for the ten consecutive business days between June 11, 2026 - June 25, 2026, the Company had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market and that this matter is now closed. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Outlook Therapeutics, Inc. Date: June 26, 2026 By: /s/ Lawrence A. Kenyon Lawrence A. Kenyon Chief Financial Officer